The global Sphingolipids Market sales was valued at approximately US$ 601.3 million in 2022. The global market is estimated to develop at a compound annual growth rate (CAGR) of 5.1% and reach a value of around US$ 991.8 Million by the end of 2032.
Sphingolipids are lipids with Sphingoid bases as their backbone, such as sphingosine. They are involved in a variety of biological activities, including tissue formation, cell identification and adhesion, and toxin receptor function. They are also important in the central nervous system.
Get Full PDF Sample Copy of Latest Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15713
The growing market for sphingolipid products is being driven by the rapid customization of sphingolipid components/formulations as well as the rising prevalence of cardiovascular illnesses worldwide, particularly among the elderly. Natural, synthetic, and semi-synthetic Sphingolipids and monomers are likely to grow in demand over the forecast period due to their use in pharmaceutical formulations.
However, the Sphingolipids market is not realising its full potential due to untapped benefits in the healthcare sector and the potential adverse effects of eating Sphingolipids incorrectly. Companies are developing novel components/formulations with low side effects and low costs in order to increase the adoption and consumption of pharmaceutical Sphingolipids. This, along with an increase in product releases and approvals, is likely to contribute to market growth during the forecast period.
North America is expected to hold the largest share of the Sphingolipids market due to the increasing demand for these compounds in the pharmaceutical industry. The presence of a well-established healthcare sector and increasing investment in research and development activities are expected to drive market growth in this region.
Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you@ https://www.futuremarketinsights.com/ask-question/rep-gb-15713
Key Takeaways from Market Study
- Sphingomyelin is the leading segment as a product and holds approximately 29.0% market share in 2021, due to its anti-cancer, bacteriostatic, and cholesterol-lowering characteristics.
- Synthetic Sphingolipids are the leading segment by source, and held about 38.4% market share in 2021, owing to their potential as therapeutic prospects for treating a range of medical problems.
- Conventional lipid-based drug delivery systems (LBDDS) is the leading segment in terms of application holding about 61.9% of the market share, as compared to traditional tablets or powder-filled capsules, as they can improve bioavailability and reduce dissolving rate-limited absorption because of their pharmacological composition in a solubilized condition.
- Semi-solid form of Sphingolipids is the leading form as of 2021, withholding about 61.9% of the global market share, owing to the property of reduced adverse side effects when a high drug load is applied to the area where the medication is actually required.
- Pharmaceutical companies are the leading end users of the global market as of 2021, withholding about 35.5% of the market share, because of increased outsourcing, innovative modalities, and creative patient outreach tactics.
- By region, North America is leading in the global Sphingolipids market and is expected to continue to do so with a projected CAGR of 5.4% during the forecasted years.
“Rising initiatives to promote health benefits of Sphingolipids products, as well as the increasing ongoing research and development in modifying novel Sphingolipids formulations is set to propel the market of Sphingolipids across the globe,” says an analyst of Future Market Insights.
Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/15713
Market Competition
Key players in the Sphingolipids Market are:
Merck KGaA, CordenPharma International, Lipoid GmbH, LARODAN AB, Croda International Plc., Biosynth, Santa Cruz Biotechnology, Inc., Creative Enzymes, CD Bioparticles, Cayman Chemical Company, and Others
Companies are actively working to increase their market share in this industry by forming strategic agreements to diversify their respective service offerings and sphingolipid production capacities.
- In January 2022, Pfizer and Acuitas Therapeutics reached an agreement on Lipid Nanoparticle Delivery System for mRNA vaccines and therapeutics.
- June 2022: To support customers’ scientific research, CD Bioparticles, enlarged its lipid system portfolio and introduced a number of Sphingolipids products. With the addition of PhosphoSphingolipids, Ceramides, Sphingolipid Metabolism, Sphingosines, GlycoSphingolipids, Phytosphingosine, and Sphingomyelin, researchers now have more options to choose from and employ in lipid system applications.
Key Segments Covered In Sphingolipids Industry Research
By Product:
- Ceramide
- Sphingomyelin
- Glucosylceramide (GlcCer)
- Lactosylceramide (LacCer)
- Ganglioside GM3
- Other
By Source:
- Synthetic
- Semi-synthetic
- Natural
By Application:
- Conventional Lipid-based Drug Delivery Systems (LBDDS)
- Self-Emulsifying Drug Delivery Systems (SEDDS)
- Self-Microemulsifying Drug Delivery Systems (SMEDDS)
- Liposomes
- Solid Lipid Nanoparticles
- Nanostructured Lipid Carriers
- Others
By Form:
- Liquid
- Semi-solid
- Solid
By End User:
- Pharmaceutical Companies
- Biopharmaceutical Companies
- Academics and Research Institutes
- Others
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs
